The Clinical Application of CD19-CART Cells



April 23, 2018

The study of CD19 CART cells is currently a hot spot for B-cell lymphomas. In 2010, Kochenderfer et al. first reported the role of CD19-CART cells in the treatment of relapsed and refractory follicular lymphoma. In 2012, Kochenderfer et al. reported that 8 patients with relapsed and refractory B-cell lymphoma received CART cell therapy, including 4 CLL, 3 follicular neoplasms, and 1 splenic marginal B-cell lymphoma.

Cancer ResearchInformatics

Keep up to date with all your favourite videos and channels.

Get personalised notifications on new releases and channel content by subscribing to the LabTube eNewsletter.